New vaccine in Scottish lab 90% effective against coronavirus
Valneva in Livingston is telling us more than 9 out of 10 people in trials developed significant levels of resistance against the virus.
Last updated 6th Apr 2021
The Scottish laboratory developing another COVID vaccine says clinical trials have not identified any safety concerns.
Valneva in Livingston is telling us more than 90-per-cent of participants developed significant levels of resistance against the virus.
A third phase of trials will begin at the end of the month.
Three dose levels of VLA2001, consisting of low, medium and high and based on a schedule of two doses with vaccinations three weeks apart, were evaluated in 153 healthy adults aged 18 to 55 years.
Valneva is revealing it is "generally safe and well tolerated" across all dose groups tested, with no safety concerns identified by an independent Data Safety Monitoring Board.
They're also certain there were no statistically significant differences between dose groups and no differences between first and second vaccinations in terms of how the subjects' bodies reacted. The majority of Adverse Events were mild or moderate and only two subjects reported a headache and fatigue.
They also ascertain VLA2001 was highly immunogenic with more than 90% of all study participants developing significant levels of antibodies to the Coronavirus SARS-CoV-2 across all groups tested.
Hear the latest news on Clyde 1 on FM, DAB, smart speaker or the Rayo app.